Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
life sciences
4
×
national blog main
boston blog main
boston top stories
startups
boston
clinical trials
financing
national top stories
san diego blog main
san diego top stories
third rock ventures
vc
20/20 healthcare partners
acetylon pharmaceuticals
ally bridge group
alnylam
ambys medicines
amgen ventures
amyotrophic lateral sclerosis
anthony despasqua
arena pharmaceuticals
artie suckow
big data analytics
blackrock
casdin capital
cell therapy
christian angermayer
constellation pharmaceuticals
deals
diabetic nephropathy
dolby family ventures
drug delivery
dtx pharma
enclear therapies
eventide asset management
focal segmental glomerulosclerosis
funding
gene therapy
What
diseases
4
×
new
4
×
medicines
biotech
develop
drugs
raised
raises
advance
aiming
ambys
analysis
associated
big
bio
biologics
bring
companies
company
considered
control
deadly
deal
debuted
deliver
device
dialysis
disease
drug
dtx
employing
enclear
formed
future
genetic
goldfinch
harmful
hitting
ipo
kidney
Language
unset
Current search:
new
×
biotech
×
diseases
×
" life sciences "
×
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
EnClear Therapies Nets $10M to Test Neuro Disease ‘Dialysis’ Device
@xconomy.com
4 years ago
DTx Pharma Raises $10.6M to Advance New Way to Deliver RNA Drugs
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?